While the S&P/ASX 200 Index (ASX: XJO) rebounded on Wednesday, it was a rough day for three ASX shares that fell roughly 9% each.
During Wednesday's session:
- Weebit Nano Ltd (ASX: WBT) fell over 9%
- Ora Banda Mining Ltd (ASX: OBM) dropped almost 10%
- 4DMedical Ltd (ASX: 4DX) shed 9%.
Single day falls of this magnitude can be the moment prospective investors wait for to enter into a company.
Here is what prompted the sell-off yesterday, and what experts are tipping for these ASX shares moving forward.
Tough week continues for Weebit Nano
Weebit Nano develops and commercialises silicon oxide and Resistive Random-Access Memory technology. Its products are used in various applications, such as in computers, consumer electronics, smartphones, tablets, enterprise storage, automotive infotainment and navigation systems, healthcare, wearables and IOT.
Its share price has tumbled for three consecutive days and now sits 13% lower than last Friday's close.
This is potentially following the same trend seen on Wall street last week.
Despite the recent sell-off, these ASX shares remain 250% higher than this time last year.
It seems the recent share price weakness could be a buy the dip opportunity for investors.
Weebit shares closed yesterday at $6.55 each.
This is significantly below recent targets from Pitt Street.
The Pitt Street team values Weebit Nano at $10.20 per share, 55% above current levels.
Ora Banda Mining remains a value play
Ora Banda Mining is a gold exploration company.
Despite yesterday's 10% fall, there was no price sensitive news out of the miner on Wednesday.
Its share price remains largely flat in 2026 compared to the start of the year, however has consistently attracted optimism from brokers.
Canaccord Genuity reiterated its buy rating recently with a $2.25 target this week.
That indicates these ASX shares could more than double in the next 12 months.
It closed yesterday at $1.09 per share.
Can 4DMedical keep soaring?
Despite falling in 2026, 4DMedical shares have risen more than 1,000% in the last 12 months.
4DMedical is a medical technology company working in the field of respiratory imaging and ventilation analysis in the treatment of lung and respiratory diseases.
Despite some share price softness this year, experts believe it can keep charging ahead long term.
MPC Markets' Mark Gardner forecasts more outperformance to come (courtesy of The Bull).
Gardner reinforced that the company has a stronger funding position after its recent capital raise and a clearer commercial pathway than in prior years.
Elsewhere, Bell Potter has a price target of $6.00 on these ASX shares.
This indicates a potential rise of 64% from current levels.
The post After dropping 9% yesterday, should you buy the dip on these ASX shares? appeared first on The Motley Fool Australia.
Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026